Stock News

Crystal Rock Capital Management Has Trimmed By $514,300 Its Wynn Resorts LTD (WYNN) Holding; 9 Analysts Are Bullish Akebia Therapeutics, Inc. (AKBA) Last Week

Crystal Rock Capital Management decreased Wynn Resorts Ltd (WYNN) stake by 9.46% reported in 2017Q3 SEC filing. Crystal Rock Capital Management sold 3,475 shares as Wynn Resorts Ltd (WYNN)’s stock rose 26.92%. The Crystal Rock Capital Management holds 33,249 shares with $4.95 million value, down from 36,724 last quarter. Wynn Resorts Ltd now has $18.46 billion valuation. The stock increased 2.37% or $4.16 during the last trading session, reaching $179.64. About 1.84M shares traded or 10.23% up from the average. Wynn Resorts, Limited (NASDAQ:WYNN) has risen 37.63% since January 21, 2017 and is uptrending. It has outperformed by 20.93% the S&P500.

Among 11 analysts covering Akebia Therapeutics Inc (NASDAQ:AKBA), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Akebia Therapeutics Inc had 24 analyst reports since August 13, 2015 according to SRatingsIntel. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities. The firm has “Buy” rating given on Tuesday, December 15 by H.C. Wainwright. The firm has “Buy” rating given on Tuesday, December 15 by Needham. The company was initiated on Tuesday, November 15 by Aegis Capital. The firm has “Buy” rating by H.C. Wainwright given on Monday, July 10. The stock has “Buy” rating by Piper Jaffray on Monday, December 18. The firm has “Buy” rating given on Tuesday, March 15 by H.C. Wainwright. H.C. Wainwright maintained Akebia Therapeutics, Inc. (NASDAQ:AKBA) rating on Wednesday, August 9. H.C. Wainwright has “Buy” rating and $2400 target. Morgan Stanley initiated the stock with “Equal Weight” rating in Thursday, August 13 report. The firm has “Neutral” rating given on Thursday, January 21 by Credit Suisse. See Akebia Therapeutics, Inc. (NASDAQ:AKBA) latest ratings:

18/12/2017 Broker: Piper Jaffray Rating: Buy New Target: $26.0 Initiate
07/12/2017 Broker: BTIG Research Rating: Buy New Target: $30.0 Initiate
02/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $17.0 Maintain
04/10/2017 Broker: Mizuho Rating: Buy New Target: $24.0 Initiate
15/09/2017 Broker: RBC Capital Markets Rating: Sector Perform New Target: $17 Initiates Coverage On
09/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $24.0000 Maintain

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor biology. The company has market cap of $695.33 million. The Company’s lead product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. It currently has negative earnings. The firm is also developing a HIF portfolio of product candidates that include AKB-6899 for the treatment of anemia; and AKB-5169, a preclinical compound for the treatment for inflammatory bowel disease.

Investors sentiment decreased to 2.23 in Q3 2017. Its down 0.02, from 2.25 in 2017Q2. It turned negative, as 17 investors sold Akebia Therapeutics, Inc. shares while 14 reduced holdings. 25 funds opened positions while 44 raised stakes. 28.78 million shares or 10.48% more from 26.05 million shares in 2017Q2 were reported. Blackrock Inc invested in 3.75M shares or 0% of the stock. Tower Research Capital Ltd (Trc) holds 1,474 shares. Piermont Cap Mgmt invested 0.18% of its portfolio in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Nationwide Fund Advisors holds 0% of its portfolio in Akebia Therapeutics, Inc. (NASDAQ:AKBA) for 23,765 shares. Trexquant L P reported 17,606 shares stake. Alliancebernstein Lp holds 43,200 shares. Nantahala Cap Limited Company has 1.37 million shares. Landscape Mgmt Ltd Limited Liability Company has invested 0.03% in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Jacobs Levy Equity Management has 21,790 shares. Barclays Public Ltd Liability Corporation stated it has 0% of its portfolio in Akebia Therapeutics, Inc. (NASDAQ:AKBA). Ameriprise Inc reported 156,500 shares. Caprock Group reported 14,450 shares stake. Manufacturers Life Insur The reported 0% stake. Numeric Ltd Liability owns 377,074 shares. Natl Bank Of Montreal Can, a Ontario – Canada-based fund reported 54,884 shares.

The stock increased 0.34% or $0.05 during the last trading session, reaching $14.71. About 222,559 shares traded. Akebia Therapeutics, Inc. (NASDAQ:AKBA) has risen 76.80% since January 21, 2017 and is uptrending. It has outperformed by 60.10% the S&P500.

Since August 15, 2017, it had 0 insider purchases, and 5 sales for $377,477 activity. Another trade for 5,000 shares valued at $75,000 was made by Dahan Michel on Tuesday, August 15. On Monday, October 2 the insider Nash Duane sold $23,332. 7,803 shares were sold by Hadas Nicole R., worth $155,188 on Monday, October 2.

Investors sentiment decreased to 1.12 in Q3 2017. Its down 0.51, from 1.63 in 2017Q2. It turned negative, as 33 investors sold WYNN shares while 148 reduced holdings. 64 funds opened positions while 138 raised stakes. 73.07 million shares or 1.76% more from 71.80 million shares in 2017Q2 were reported. California State Teachers Retirement Sys stated it has 0.04% of its portfolio in Wynn Resorts, Limited (NASDAQ:WYNN). Lakeview Capital Ptnrs Ltd Liability Corporation invested in 2,750 shares. Kbc Grp Inc Nv holds 0.02% in Wynn Resorts, Limited (NASDAQ:WYNN) or 17,322 shares. 2,520 are owned by Coastline. Prudential Finance owns 0.03% invested in Wynn Resorts, Limited (NASDAQ:WYNN) for 119,621 shares. Connor Clark And Lunn Invest Mngmt Limited accumulated 3,125 shares. Verition Fund Ltd Liability holds 0.04% or 3,353 shares. 7,696 were accumulated by Profund Advsr Limited Liability Corporation. Mirae Asset Global Invests Limited owns 0.01% invested in Wynn Resorts, Limited (NASDAQ:WYNN) for 5,018 shares. Chesley Taft And Associates Limited Liability Co stated it has 10,010 shares. Commercial Bank Of Nova Scotia stated it has 0.01% in Wynn Resorts, Limited (NASDAQ:WYNN). Morgan Stanley holds 778,204 shares. Mackenzie Financial has invested 0.02% in Wynn Resorts, Limited (NASDAQ:WYNN). Secor Capital Advsr LP has invested 0.33% in Wynn Resorts, Limited (NASDAQ:WYNN). Davidson Kempner Capital Management Lp holds 237,500 shares or 1.05% of its portfolio.

Since July 31, 2017, it had 0 buys, and 3 insider sales for $9.62 million activity. MADDOX MATT sold 42,900 shares worth $6.15M. The insider Randt Clark T. Jr. sold 3,000 shares worth $387,000. On Friday, September 15 the insider Sinatra Kimmarie sold $3.08M.

Analysts await Wynn Resorts, Limited (NASDAQ:WYNN) to report earnings on January, 25. They expect $1.32 earnings per share, up 164.00% or $0.82 from last year’s $0.5 per share. WYNN’s profit will be $135.67 million for 34.02 P/E if the $1.32 EPS becomes a reality. After $1.52 actual earnings per share reported by Wynn Resorts, Limited for the previous quarter, Wall Street now forecasts -13.16% negative EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *